Intra-Cellular Therapies, Inc.
42
15
15
24
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
7.1%
3 terminated/withdrawn out of 42 trials
88.9%
+2.4% vs industry average
45%
19 trials in Phase 3/4
63%
15 of 24 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (42)
Caplyta in Borderline Personality Disorder
Role: collaborator
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
Role: lead
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
Role: lead
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Role: lead
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Role: lead
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Role: lead
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Role: lead
Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Role: lead
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Role: lead
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Role: lead
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
Role: lead
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Role: lead
A Trial to Assess the Antipsychotic Efficacy of ITI-007
Role: lead
A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects
Role: lead
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Role: lead
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Role: lead
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Role: lead
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Role: lead
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
Role: lead
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Role: lead